Search results

1410 results

Sorted by Relevance . Sort by Date

  1. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet

  2. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza)

  3. Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)

    Evidence-based recommendations on inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)

  4. Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

    Evidence-based recommendations on cabazitaxel (Jevtana) for prostate cancer that has come back after it was treated with docetaxel

  5. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

  6. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

  7. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

  8. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

    Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600

  9. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus

  10. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del

  11. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

    Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults

  12. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction

  13. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

    Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine

  14. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults

  15. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had

  16. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer

  17. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases

  18. Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

  19. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion

  20. Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

    Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing

  21. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases

  22. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab

  23. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

  24. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C

  25. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in people having a liver transplant

  26. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema in adults

  27. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

  28. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for moderately to severely active Crohn's disease if TNF-alpha therapy has not worked or...

  29. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

  30. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

    Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults

  31. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia

  32. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

    Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary

  33. Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

    Evidence-based recommendations on nivolumab (Opdivo) for locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

  34. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

    Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in

  35. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

  36. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

    Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

  37. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults

  38. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

    Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)